Valuation: Amarin Corporation plc

Market Cap 293M 255M 242M 219M 410M 28.06B 412M 2.88B 1.11B 14.26B 1.1B 1.08B 45.65B P/E 2026 *
-198x
P/E 2027 * -231x
Enterprise Value 131M 114M 108M 97.89M 183M 12.52B 184M 1.28B 496M 6.36B 491M 480M 20.36B EV / Sales 2026 *
0.74x
EV / Sales 2027 * 0.67x
Free-Float
86.93%
Yield 2026 *
-
Yield 2027 * -
1 week+0.84%
Current month+0.84%
3 months-6.25%
6 months-9.77%
Current year+0.84%
1 week 11.6
Extreme 11.6
12
1 month 11.4
Extreme 11.4
12.2
Current year 11.2
Extreme 11.2
14.1
1 year 11.2
Extreme 11.2
17.2
3 years 5.92
Extreme 5.92
25.2
5 years 5.92
Extreme 5.92
98
10 years 5.92
Extreme 5.92
540
Manager TitleAgeSince
Chief Executive Officer 63 2024-06-03
Director of Finance/CFO 42 2024-10-22
Compliance Officer 56 2023-11-14
Director TitleAgeSince
Director/Board Member 63 2024-06-03
Director/Board Member 43 2023-02-27
Director/Board Member 67 2023-02-27
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.84% - - 292M
+1.76%+3.88%+46.85%+101.12% 69.69B
+2.29%+1.43%+38.39%+77.03% 61.24B
+1.14%-2.59%-14.37%+365.92% 26.77B
+2.95%+2.34%+0.52%-12.74% 24.07B
+1.49%+7.73%+26.85%-15.89% 20.39B
-0.83%-9.47%+174.16%+295.44% 15.72B
+3.01%+1.85%+44.63%+168.18% 14.07B
+2.43%+4.24%-2.05%+847.59% 13.8B
+1.00%+0.24%+28.02%+203.83% 12.22B
Average +1.52%+0.66%+38.11%+225.61% 28.66B
Weighted average by Cap. +1.82%+1.73%+36.71%+163.30%

Financials

2026 *2027 *
Net sales 177M 155M 146M 133M 248M 16.99B 250M 1.74B 674M 8.64B 667M 652M 27.65B 177M 154M 146M 132M 247M 16.94B 249M 1.74B 671M 8.61B 664M 650M 27.55B
Net income -26.62M -23.19M -21.95M -19.94M -37.25M -2.55B -37.44M -261M -101M -1.3B -100M -97.79M -4.15B -18.32M -15.96M -15.1M -13.72M -25.63M -1.75B -25.76M -180M -69.55M -892M -68.82M -67.29M -2.85B
Net Debt -162M -141M -134M -122M -227M -15.54B -228M -1.59B -616M -7.9B -610M -596M -25.28B -175M -152M -144M -131M -245M -16.75B -246M -1.72B -664M -8.51B -657M -642M -27.25B
Logo Amarin Corporation plc
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Employees
80
Date Price Change
26-09-17 €11.90 -0.83%
26-09-16 €12.00 +0.84%
26-09-15 €11.90 -0.83%
26-09-14 €12.00 +0.84%
26-09-11 €11.90 0.00%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
13.87USD
Average target price
12.50USD
Spread / Average Target
-9.88%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!